Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New study tests Adebrelimab's Real-World impact on tough lung cancer

NCT ID NCT07434518

First seen Mar 07, 2026 · Last updated Jun 16, 2026 · Updated 16 times

Summary

This study looks at how well the drug adebrelimab works and how safe it is for people with advanced small cell lung cancer in everyday medical practice. Researchers will track 500 patients to see side effects, survival time, and how long the cancer stays under control. The goal is to understand the drug's real-world benefits beyond clinical trials.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SMALL CELL LUNG CANCER (SCLC) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Shanghai General Hospital

    RECRUITING

    Shanghai, 201620, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

The condition(s) this trial relates to.

small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.